Neurodevelopmental outcomes of children born to diabetic mothers in the Qatari population: a retrospective study

• by Razan M Masri, Mohammad A A Bayoumi, Rasha I Amin, Hafsa O A Alsharif, Amna Musa, Ahmad S Mudrek, Basma A M R Selim, Prem Chandra, Samah Elshaar

• May 22, 2026

Development and application of a quality evaluation scale for ERAS health education in gynecologic malignancies

• by Jianmin Feng, Lu Wang, Hanlin Yang, Weijie Tian, Yuan Gong, Yan Zhu, Dan Zi

• June 30, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

• by Kathryn Wighton

• June 26, 2026

• 3 min

Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer

Roswell Park Comprehensive Cancer Center is currently recruiting for a phase 1 clinical trial of the new therapy (NCT07489287), called GB-5267, which was co-developed by Roswell Park and the therapeutics company Generate:Biomedicines.

• June 24, 2026

• 3 min